Intelligence coverage: 60%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

HAE

HAEMONETICS CORP

Healthcare · Medical Instruments & Supplies

$105.79Sep 28, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

HAEMONETICS CORP shows stable business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue +6% YoY in Q1 FY2027.

TrajectoryStable

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue +6% YoY in Q1 FY2027

Pipeline evidence · 0d ago

HAE's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on HAE.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q1 2027

Full HAE earnings analysis

Reported figures for HAEMONETICS CORP — research only, not investment advice.

Revenue YoY
+5.6%
EPS YoY
+2.9%

Latest Intelligence

Updated

What happened recently for HAEMONETICS CORP (HAE) — events, not interpretation.

Event
Reported Q1 2027 revenue +6% YoY.
Also
Last session September 28, 2026 at $105.79.
Source
Q1 2027 earnings

Research & analysis only — not investment advice.

Building company intelligence…

HAEMONETICS CORP (HAE)

Healthcare · Medical Instruments & Supplies

Investment Snapshot above is the primary AlphaOS analysis for HAEMONETICS CORP — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Market cap:
$4.81B
Revenue:
$339.38M

HAE earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow HAEMONETICS CORP through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.

Structured stock intelligence for companies connected to this research.